Found: 1
Select item for more details and to access through your institution.
Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/ mTOR pathway via targeting JAK-STAT signaling of CD4<sup>+</sup> cells.
- Published in:
- Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1324892
- By:
- Publication type:
- Article